# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Franklin D. Roosevelt (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET002-SYN
- Date: 2026-04-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Nathaniel Brooks, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week heart failure medication safety check, echocardiogram, and cardiology review. **S**

## History of present illness

Mr. Roosevelt returns two weeks after starting sacubitril/valsartan, carvedilol, empagliflozin, and furosemide for newly diagnosed heart failure. He is less breathless: he now propels his wheelchair the length of a long corridor before he has to rest, and he sleeps on two pillows without waking breathless. His leg swelling is less by evening. His home weights on a wheelchair scale have fallen by about 3 kg, and his home blood pressures run in the 140s over 80s. He has had no lightheadedness on transfers, no lip or tongue swelling, and no genital itching or urinary symptoms, and he has taken every dose. He still tires by late afternoon. He stopped smoking on his quit date last week and wears the nicotine patch every day; cravings come mostly in long meetings. He has had no muscle aches on atorvastatin. His echocardiogram and cardiology consultation were done this morning. **S**

| Element | Detail |
|---|---|
| Interval change | Propels a long corridor before resting; two pillows; less evening leg swelling |
| Weight log | Down about 3 kg on the home wheelchair scale |
| Home blood pressure | 140s over 80s |
| Medication tolerance | No lightheadedness on transfers, angioedema, genital or urinary symptoms, or muscle aches |
| Tobacco | No cigarettes since his quit date last week; nicotine patch daily |
| NYHA class | II to III, improved from III |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tires by late afternoon, less than before treatment; no fever |
| Cardiovascular | Positive | Mild leg swelling by evening; sleeps on two pillows; no chest pain or palpitations |
| Respiratory | Positive | Breathless after propelling his wheelchair a long corridor; morning smoker's cough, less since he stopped smoking |
| Genitourinary | Negative | No dysuria or genital itching |
| Neurological | Negative | No lightheadedness on transfers |
| Musculoskeletal | Negative | No muscle aches or cramps |

6 systems reviewed. **S**

## Current medications

- Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice daily **S**
- Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with food **S**
- Spironolactone 25 mg oral tablet, one tablet by mouth daily **S**
- Empagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Furosemide 20 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Nicotine 21 mg/24 hr transdermal patch, apply one patch daily **S**
- Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart **S**

## Allergies

- No known allergy **S**

## Objective

BP 148/88 mmHg; pulse 84 bpm; respirations 18/min; temperature 36.8 °C; oxygen saturation 95% on room air; weight 85 kg; BMI 24 kg/m². All vital signs are synthetic.

Sodium: 136 mmol/L; Potassium: 4.8 mmol/L; Creatinine: 1.29 mg/dL; eGFR: 63 mL/min/1.73 m²; Glucose: 98 mg/dL; LVEF by echocardiogram: 30% (low). All results are synthetic.

## Change since baseline

- Sodium: 137 mmol/L at baseline, 136 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Creatinine: 1.18 mg/dL at baseline, 1.29 mg/dL at this visit **S**
- eGFR: 70 mL/min/1.73 m² at baseline, 63 mL/min/1.73 m² at this visit **S**
- Glucose: 104 mg/dL (high) at baseline, 98 mg/dL at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Alert and comfortable at rest in his wheelchair; speaks in full sentences; weight 85 kg on the wheelchair scale, down 3 kg in two weeks |
| Neck | Jugular venous pressure 9 cm at 45 degrees |
| Lungs | Fine crackles at both bases |
| Heart | Regular rhythm, rate 84; S3; apical impulse displaced laterally |
| Extremities | 1+ symmetric edema at the ankles and shins |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with reduced ejection fraction, improving** (I50.22). Echocardiography today shows a left ventricular ejection fraction of 30 percent, confirming heart failure with reduced ejection fraction. He is better but still mildly congested (jugular venous pressure 9 cm, basal crackles, 1+ edema); NYHA class II to III. After two weeks of sacubitril/valsartan, empagliflozin, and furosemide, potassium is 4.8 mmol/L and creatinine 1.29 mg/dL (eGFR 63), a 9 percent rise that is well within the 30 percent accepted when this therapy starts. **S**
   - Increase sacubitril/valsartan to 49/51 mg twice daily.
   - Increase carvedilol to 6.25 mg twice daily with food.
   - Start spironolactone 25 mg daily: potassium is below 5.0 mmol/L and eGFR above 30.
   - Continue empagliflozin 10 mg daily and furosemide 20 mg daily.
   - Basic metabolic panel in one to two weeks, drawn at the second iron infusion, because sacubitril/valsartan rises and spironolactone starts today.
   - Cardiology agrees with the titration plan; repeat echocardiogram three to six months after tolerated doses are reached.
2. **Iron deficiency in heart failure** (D50.9). Ferritin 48 ng/mL and transferrin saturation 16 percent at diagnosis, with hemoglobin 12.6 g/dL. This meets the heart failure criteria for intravenous iron, which improves symptoms and exercise capacity. **S**
   - Ferric carboxymaltose 750 mg intravenously today and again in one week.
   - Recheck hemoglobin, ferritin, and transferrin saturation at the three-month review.
3. **Hypertensive heart disease** (I11.0). Blood pressure 148/88 mmHg, down from 186/108 at diagnosis but above the 130/80 target; home readings agree. **S**
   - Today's increases in sacubitril/valsartan and carvedilol and the new spironolactone are expected to lower it.
   - Continue the home blood pressure and daily weight log and the low-sodium diet.
4. **Nicotine dependence, cigarettes, newly abstinent** (F17.210). No cigarettes since his quit date last week, on a 21 mg nicotine patch. **S**
   - Continue the patch daily.
   - Plan for meeting cravings reviewed: leave the room briefly, and keep his hands busy.
5. **Hyperlipidemia** (E78.5). Atorvastatin 40 mg started two weeks ago for LDL cholesterol 132 mg/dL; no muscle symptoms. **S**
   - Lipid panel 4 to 12 weeks after the start, to confirm the response.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Basic metabolic panel | 1 to 2 weeks after starting or changing sacubitril/valsartan, spironolactone, empagliflozin, or a diuretic; every 3 to 6 months when stable | Completed today | Two weeks after starting sacubitril/valsartan, empagliflozin, and furosemide. Sodium 136, potassium 4.8, creatinine 1.29 mg/dL (up 9 percent), eGFR 63 |
| Laboratory | Basic metabolic panel after today's changes | 1 to 2 weeks after titrating sacubitril/valsartan or starting spironolactone | Due | Both change today; to be drawn at the second iron infusion next week |
| Imaging | Transthoracic echocardiogram | At diagnosis; repeat 3 to 6 months after therapy is optimized, or with unexplained change | Completed today | Ejection fraction 30 percent: heart failure with reduced ejection fraction. Repeat after tolerated doses are reached, to decide on device therapy |
| Imaging | 12-lead ECG | At initial evaluation; repeat with symptom change, arrhythmia, or device consideration | Deferred | No ECG from the diagnostic workup is on file, a deviation from the protocol. Rhythm is regular on examination and no device decision is due yet, so no harm has resulted. Corrective action: obtain an ECG before the device decision that follows the repeat echocardiogram |
| Laboratory | Liver tests (initial workup; ALT before starting a statin) | Once at diagnosis | Deferred | No liver panel from the diagnostic visit is on file, a deviation from the heart failure and lipid protocols. He has no symptoms of liver injury. Routine liver monitoring on a statin is not recommended, so the corrective action is to test ALT only if symptoms appear |
| Laboratory | NT-proBNP | At diagnosis; selectively in outpatient follow-up | Not indicated | 2850 pg/mL at diagnosis. Not used to titrate therapy; repeat at the three-month review to gauge decongestion |
| Laboratory | Hemoglobin, ferritin, and transferrin saturation | At diagnosis; reassess 6 to 8 weeks after intravenous iron | Due | Iron deficiency at diagnosis; intravenous iron starts today. The recheck is planned for the three-month review, about ten weeks after the second dose, to spare him an extra trip: a planned two-week departure from the anemia monograph's window |
| Referral | Endoscopy and colonoscopy for iron deficiency anemia | At diagnosis of iron deficiency anemia in an adult man | Not indicated | Ferritin 48 ng/mL is above the 30 ng/mL threshold for absolute iron deficiency. His iron deficiency is the functional deficiency of heart failure, defined by a transferrin saturation below 20 percent. Routine colorectal cancer screening is still to be addressed |
| Examination | Blood pressure, heart rate, weight, jugular venous pressure, edema, lungs | Every visit; every 1 to 2 weeks during titration | Completed today | Weight down 3 kg; still mildly congested |
| Survey | NYHA functional class | Every visit | Completed today | Class II to III |
| Survey | KCCQ-12 | Baseline, then every 3 to 6 months | Up to date | Baseline 38 two weeks ago; next at the three-month review |
| Survey | Depression screen (PHQ-2) | Periodically | Up to date | Score 1 at diagnosis |
| Referral | Cardiology consultation | At diagnosis, to confirm the diagnosis and guide titration | Completed today | Seen today; agrees with the titration plan |
| Referral | Cardiac rehabilitation | Ejection fraction 35 percent or less, NYHA II to IV, after 6 weeks of optimal therapy | Due | Eligible by ejection fraction; reassess at the three-month review, once he has had six weeks of therapy |
| Medication safety | Tolerance of sacubitril/valsartan, carvedilol, and empagliflozin | Each visit while titrating | Completed today | No hypotension, angioedema, bradycardia, volume depletion, or genital infection |
| Medication safety | Pneumococcal vaccine | Once, for chronic heart disease and smoking | Completed today | PCV20 given today |
| Medication safety | Tobacco use and cessation treatment | Every visit | Completed today | Abstinent since his quit date last week; nicotine patch continued |
| Laboratory | Lipid panel | 4 to 12 weeks after starting a statin | Due | Atorvastatin started two weeks ago |
| Laboratory | HbA1c, urine albumin-creatinine ratio, and TSH | HbA1c and urine albumin yearly; TSH at diagnosis | Up to date | HbA1c 5.9 percent, urine albumin-creatinine ratio 64 mg/g, and TSH 2.1 at diagnosis. The urine albumin test is repeated at the six-month review, because a single raised value can fall as blood pressure comes down |
| Self-management | Home blood pressure and daily weight log; low-sodium diet | Every visit | Completed today | Log reviewed; weights falling and blood pressures recorded twice daily |

## Goal progress

- Lower blood pressure below 130/80 by the six-month review. In progress; target 2026-09-25. **S**
- Improve the KCCQ-12 overall summary score by at least 20 points by the three-month review. In progress; target 2026-06-26. **S**
- Stop smoking by the three-month review. In progress; target 2026-06-26. **S**
- Reach the highest tolerated doses of guideline-directed therapy by the six-month review. In progress; target 2026-09-25. **S**

## Medication changes

- Stopped: Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet by mouth twice daily **S**
- Started: Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet by mouth twice daily **S**
- Stopped: Carvedilol 3.125 mg oral tablet, one tablet by mouth twice daily with food **S**
- Started: Carvedilol 6.25 mg oral tablet, one tablet by mouth twice daily with food **S**
- Started: Spironolactone 25 mg oral tablet, one tablet by mouth daily **S**
- Started: Ferric carboxymaltose 750 mg in 15 mL intravenous infusion, two doses one week apart **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology
- CMID: Clinical Monitoring Intelligence Database, heart failure and hypertension monographs (2026), Aether Forge
- Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions (2021), U.S. Preventive Services Task Force
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force

## Follow-up

- Basic metabolic panel with the second iron infusion next week. Three-month heart failure and blood pressure review with laboratory tests and the KCCQ-12. **S**
- Next scheduled visit 2026-06-26: three-month heart failure and blood pressure review. **S**
